Abstract: The present disclosure relates to the field of biomedicine, and in particular, to an improved mutant of a respiratory syncytial virus (RSV) fusion (F) protein and uses thereof. The mutant can form a trimeric structure without introducing a heterologous trimerization domain. Meanwhile, through mutation designs such as releasing internal electrostatic repulsion, deleting the furin cleavage site, truncating the C-terminal domain, and introducing interchain disulfide bonds, the protein is stabilized in the pre-fusion conformation and exhibits enhanced stability. The mutant in the present disclosure is highly immunogenic when used as a vaccine or a vaccine component and can induce the production of a high level of neutralizing antibodies in the immunized animal, which can be used in the preparation of a vaccine for the prevention or treatment of RSV infection, and can also be used as a reagent for the detection of RSV.

Abstract: The present disclosure relates to the field of biomedicine, and in particular, to an improved mutant of a respiratory syncytial virus (RSV) fusion (F) protein and uses thereof. The mutant can form a trimeric structure without introducing a heterologous trimerization domain. Meanwhile, through mutation designs such as releasing internal electrostatic repulsion, deleting the furin cleavage site, truncating the C-terminal domain, and introducing interchain disulfide bonds, the protein is stabilized in the pre-fusion conformation and exhibits enhanced stability. The mutant in the present disclosure is highly immunogenic when used as a vaccine or a vaccine component and can induce the production of a high level of neutralizing antibodies in the immunized animal, which can be used in the preparation of a vaccine for the prevention or treatment of RSV infection, and can also be used as a reagent for the detection of RSV.